Jan 14, 2019
NEW YORK (GenomeWeb)
“FDNA is planning a soft launch for a new iteration of its Face2Gene software, which integrates information from facial anomalies with phenotypic traits and variant information to diagnose genetic disorders, that is intended for integration with commercial bioinformatics software packages and products. The planned update is set to launch at the end of the first quarter. FDNA is currently working with early adopters to pilot the yet-to-be-named product. Integrating the software with existing software products at clinical laboratories, for example, will help them include the results of facial analysis in the genetic test results that they offer to clinicians. Earlier this week, the company published a new study in Nature Medicine, that describes DeepGestalt, the deep learning-based algorithm that underlies its Facial Dysmorphology Novel Analysis, or FDNA, technology”
FDNA is set to launch a new version of its facial analysis software for commercial integration in the first quarter, as reported by GenomeWeb. This advanced software leverages artificial intelligence to analyze facial features, aiding in the diagnosis of genetic disorders. The upgraded version aims to enhance diagnostic accuracy and integrate seamlessly with existing healthcare systems. By doing so, FDNA’s facial analysis software can provide healthcare professionals with a powerful decision support tool for identifying rare genetic conditions more efficiently. This article highlights FDNA’s commitment to innovation and improving patient outcomes through cutting-edge technology.
